Skip to main content

Table 3 Comparison of shoulder ratings before and 6 weeks after ESWT/sham treatment in the study or placebo groups

From: Short-term outcomes of extracorporeal shock wave therapy for the treatment of chronic non-calcific tendinopathy of the supraspinatus: a double-blind, randomized, placebo-controlled trial

CMS

ESWT

PLACEBO

P value1

PAIN

   

Baseline

2.72 ± 2.61 (0-5)

3.33 ± 2.5 (0-5)

0.592

6 weeks

8.18 ± 3.37 (5-15)

4.44 ± 3.9 (0-10)

0.045

P value2

0.006

0.414

 

ADL

   

Baseline

10.27 ± 3.28 (5-18)

11.55 ± 4.21 (6-18)

0.378

6 weeks

15.1 ± 3.83 (7-20)

11 ± 5.48 (2-20)

0.068

P value2

0.01

0.674

 

ROM

   

Baseline

16.18 ± 4.68 (10-24)

16.67 ± 8.36 (2-26)

0.878

6 weeks

27.27 ± 8.5 (12-40)

17.1 ± 9.06 (8-32)

0.038

P value2

0.006

0.618

 

POWER

   

Baseline

13.27 ± 5.4 (5-20)

10.11 ± 3.18 (5-15)

0.170

6 weeks

13.36 ± 4.3 (7-18)

10.55 ± 4.21 (6-19)

0.174

P value2

0.834

0.726

 

TOTAL

   

Baseline

42.45 ± 9.83 (29-61)

41.67 ± 12.53 (20-57)

0.970

6 weeks

64 ± 16.6 (32-87)

43.11 ± 19.16 (18-70)

0.018

P value2

0.004

0.368

 
  1. The values are given as mean ± standard deviation (range).
  2. 1 Comparison between treatment and control group both before and after treatment (Mann-Whitney U- test).
  3. 2 Comparison between before and after treatment within each group (Wilcoxon test).
  4. ESWT, indicates extracorporeal shock wave therapy; ADL, activity of daily living; ROM, range of motion; CMS, Constant and Murley Score.